Ortho Regenerative Technologies Closes Private Placement

Ortho Regenerative Technologies closed an oversubscribed non-brokered private placement of units for $3.2 million.

Net proceeds will be used to initiate enrollment and fund advancement of the ORTHO-R Phase I/II U.S. clinical trial for rotator cuff tear repair, as well as working capital and general corporate purposes.

ORTHO-R is the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us